Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cinitapride + pantoprazole
- Development stage
- Unknown
- Lead developer
- Waterley Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cretox-CP is a fixed-dose combination pharmaceutical product developed by Waterley Pharmaceuticals, primarily indicated for the treatment of gastroesophageal reflux disease (GERD) and functional dyspepsia. The medication combines two active ingredients with complementary mechanisms: **cinitapride** and **pantoprazole**. Cinitapride is a substituted benzamide prokinetic agent that acts as a selective 5-HT4 receptor agonist and 5-HT2 receptor antagonist, thereby increasing lower esophageal sphincter tone and accelerating gastric emptying. Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cells. By addressing both impaired gastrointestinal motility and acid overproduction, Cretox-CP provides symptomatic relief for patients suffering from acid reflux, heartburn, and indigestion.
- Brand names
- Cretox-CP
- Other names
- Cinitapride and Pantoprazole Sodium Tablets
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on cinitapride + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cinitapride + pantoprazole.